3/5Checkpoint Therapeutics, Inc. (CKPT): Going-concern doubt

Market data

Price before filing: $4.16 (2025-05-12 close, split/dividend-adjusted)
Market cap at flag: $248.3M (2025-05-13) · Latest: $254.8M (2025-05-30)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: 2 insiders sold $111K (2 sales)
30 days after: 1 insider sold $129K (1 sale)

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-02-12 to 2025-06-12. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"We have not generated any sales revenue from our development stage products, and we do not know when, or if, we will generate any revenue from sales of UNLOXCYT. ● There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. ● Our success is contingent upon raising additional capital for our development programs and commercialization efforts,..."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2025-03-31)

Why this score: quarterly (unaudited) disclosure